Costimulatory b7-h1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target

Abstract

The invention features methods of diagnosis by assessing B7-H1 expression in a tissue from a subject that has, or is suspected of having, cancer, methods of treatment with agents that interfere with B7-H1-receptor interaction, methods of selecting candidate subjects likely to benefit from cancer immunotherapy, and methods of inhibiting expression of B7-H1.

1 . (canceled) 
     
     
         2 . A method for treating an immunosuppression characterized by an impaired function and survival of activated tumor-specific T-cells in a subject with cancer comprising administering, to said subject, an agent which is an antibody or an antigen-binding antibody fragment that interferes with an interaction between B7-H1 and a receptor for B7-H1, wherein some or all cells of said cancer express B7-H1, wherein said subject is a human and said B7-H1 is human B7-H1 (hB7-H1), wherein said agent binds to said receptor for hB7-H1, wherein said receptor is the PD-1 receptor, and wherein said cancer is a renal cell carcinoma. 
     
     
         3 . The method of  claim 2 , wherein said agent is an antibody. 
     
     
         4 . The method of  claim 2 , wherein said agent is a humanized antibody. 
     
     
         5 . The method of  claim 2 , wherein said agent is an IgG antibody. 
     
     
         6 . The method of  claim 2 , wherein said agent is a monoclonal antibody. 
     
     
         7 . The method of  claim 2 , wherein said agent is a fragment of a monoclonal antibody.